Watch Ticker

TScan Therapeutics, Inc. Common Stock

Go to TScan Therapeutics, Inc. Common Stock Website

$1.71

0.09 (5.56%)

Live

Previous Close

$1.62

Day Range

$1.615 - $1.73

Previous Day Range

$1.6021 - $1.7677

Market Cap

$91.7 million USD

Day Vol.

171322

Previous Day Vol.

462396

Currency

USD

Primary Exchange

Nasdaq

TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and ...

Community

0 posts discussing

0

Watchers

0

Visitors

Recent News

N/A - TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference

TScan Therapeutics, a clinical-stage biotechnology company, announced updates from its PLEXI-T solid tumor and ALLOHA heme Phase 1 clinical trials, and plans to file an IND application for TSC-102-A0301 (CD45; HLA-A*03:01) with the FDA.

Related tickers: TCRX.

Read Full Article

Prnewswire - New Data and Deal Flow Signal a Turning Point for Precision-Driven Cancer Biotechs

The article discusses the growing cancer treatment market, with a focus on companies like Oncolytics Biotech, Akoya Biosciences, Quanterix, TScan Therapeutics, and Arcellx. It highlights new data and collaborations that signal a turning point for precision-driven cancer biotechs.

Related tickers: ONCY, AKYA, QTRX, TCRX, ACLX.

Read Full Article

Trending Tickers

Please sign in to view